Swaffham & Downham Inhaler Optimisation Programme

Practice Pro-Forma

Dear Practice,

Following on from the work proposed for the IIF 2022/2023, we are keen to continue efforts to support the PCN practices in optimising their eligible patients from metred dose inhalers to dry powder inhalers. This will be both cost- and carbon-saving for the NHS. 

We propose a PCN-wide inhaler optimisation project to: identify, engage with, educate and consent patients for the inhaler switch, promoting a change to the easier-to-use and carbon friendlier dry powder inhalers.

The first phase of automated patient engagement will be to your patients currently prescribed Clenil Modulite, to counsel and consent them to be switched to Easyhaler Beclometasone, a carbon-neutral and cost-effective inhaler alternative.   

This process will take the form of: SMS text automatically sent to the select patient cohort via Eclipse, directing them to a link which contains a patient information zone, explaining the benefits of switching and how to use the new inhaler. At the bottom of this page will be a link to their secure patient portal, where they can complete a short questionnaire and consent to the switch and have their baseline symptomatology assessed.

Responses will form patient lists within Eclipse for the various outcomes, for example:

  • Patients wishing to be switched to Easyhaler Beclometasone

  • Patients requiring more information before being switched

  • Patients not wanting to be switched to Easyhaler Beclometasone

Your practice prescribing team will be provided with a guide and, if desired, Teams-based training on how to use Eclipse to conduct these reviews and document the outcomes.

Please complete the pro forma details below to activate this programme.